Literature DB >> 9589847

Safety considerations in treating concomitant diseases in patients with asthma.

L W Hunt1.   

Abstract

The treatment for asthma usually involves a combination of drugs used for bronchodilation and to treat underlying airway inflammation. When asthma is severe, the regimen used to treat asthma can become quite complicated, often using as many as 3 or 4 separate pharmacological agents. As patients with asthma get older, their medication regimen can become even more complex with the development of numerous other age-related diseases requiring their own list of medications. Diseases of the joints, diseases of the eye, cardiovascular disease, neurological disease and urological problems represent the most common conditions that patients develop, at times needing medications which might interfere with asthma management. Many of these diseases require the use of nonsteroidal anti-inflammatory agents, well known to provoke wheezing in patients with intrinsic asthma, and diseases of the eye and cardiovascular system frequently require use of beta-blockers which can cause or exacerbate asthma. Managing patients with asthma who have other diseases requires constant supervision of their medication usage and careful and cautious review of the entire list of medications at each presentation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9589847     DOI: 10.2165/00002018-199818050-00005

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  96 in total

Review 1.  The cardioselectivity of beta adrenoceptor antagonists.

Authors:  T H Pringle; J G Riddell
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

2.  Transdermal delivery of mepindolol and propranolol in normal man. 2nd communication: pharmacokinetic and neuro-endocrine aspects.

Authors:  C de Mey; I Meineke; D Enterling; C Rehbock; H Osterwald
Journal:  Arzneimittelforschung       Date:  1989-11

3.  Intolerance to aspirin. Clinical studies and consideration of its pathogenesis.

Authors:  M Samter; R F Beers
Journal:  Ann Intern Med       Date:  1968-05       Impact factor: 25.391

4.  Pretreatment with an antibody to interleukin-5 prevents loss of pulmonary M2 muscarinic receptor function in antigen-challenged guinea pigs.

Authors:  C L Elbon; D B Jacoby; A D Fryer
Journal:  Am J Respir Cell Mol Biol       Date:  1995-03       Impact factor: 6.914

5.  Severe anaphylaxis and drug-induced beta-blockade.

Authors:  P J Hannaway; G D Hopper
Journal:  N Engl J Med       Date:  1983-06-23       Impact factor: 91.245

Review 6.  Medications used to prevent migraine headaches and their potential ocular adverse effects.

Authors:  M J Doughty; W M Lyle
Journal:  Optom Vis Sci       Date:  1995-12       Impact factor: 1.973

7.  Diagnosis, prevention, and treatment of adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs.

Authors:  D D Stevenson
Journal:  J Allergy Clin Immunol       Date:  1984-10       Impact factor: 10.793

8.  The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics.

Authors:  B Dahlén; M Kumlin; D J Margolskee; C Larsson; H Blomqvist; V C Williams; O Zetterström; S E Dahlén
Journal:  Eur Respir J       Date:  1993-07       Impact factor: 16.671

9.  Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma.

Authors:  K Sladek; A Szczeklik
Journal:  Eur Respir J       Date:  1993-03       Impact factor: 16.671

10.  beta-2 Adrenergic blockade evaluated with epinephrine after placebo, atenolol, and nadolol.

Authors:  W R Hiatt; E E Wolfel; S Stoll; A S Nies; G O Zerbe; H L Brammell; L D Horwitz
Journal:  Clin Pharmacol Ther       Date:  1985-01       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.